Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sohini Mondal

RARE PHOTOS: Moderna stock analyst estimates ratings - The Real Truth

With a market cap of $9.3 billion, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development of messenger RNA (mRNA) therapeutics and vaccines. Known for its COVID-19 vaccine Spikevax, the company also advances treatments across infectious diseases, oncology, and rare diseases, and has formed numerous strategic global partnerships.

Shares of the Cambridge, Massachusetts-based company have significantly underperformed the broader market over the past 52 weeks. Moderna has decreased 80.1% over this time frame, while the broader S&P 500 Index ($SPX) has gained 8.7%. Moreover, MRNA stock has declined 41.5% on a YTD basis, compared to SPX's 4.1% decline.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.